Long-term outcomes of salvage endoscopic submucosal dissection for local failure after chemoradiotherapy for esophageal squamous cell carcinoma.


Journal

Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225

Informations de publication

Date de publication:
01 Jul 2021
Historique:
received: 09 11 2020
accepted: 13 02 2021
pubmed: 25 3 2021
medline: 8 7 2021
entrez: 24 3 2021
Statut: ppublish

Résumé

Salvage endoscopic submucosal dissection is considered a minimally invasive treatment for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. However, the long-term outcomes have not been fully evaluated. This study investigated the short-term and long-term outcomes of salvage endoscopic submucosal dissection. Patients who underwent endoscopic submucosal dissection for local recurrence or residual tumor after chemoradiotherapy from January 2006 to December 2017 were retrospectively investigated. Follow-up included endoscopic examination and computed tomography at least once every 6 months after salvage endoscopic submucosal dissection. Risk factors for disease recurrence after salvage endoscopic submucosal dissection were assessed using the Cox hazards model. A total of 30 patients (33 cases of esophageal squamous cell carcinoma: local recurrence, n = 27; residual tumor, n = 6) were included. The median endoscopic submucosal dissection procedure time was 40 min (interquartile range [IQR], 33-58.5 min). En bloc resection was achieved in 31 (94%) of 33 esophageal squamous cell carcinoma cases. One patient with intraoperative perforation did not require surgical intervention and recovered with conservative treatment. A total of 16 patients (53%) had disease recurrence at a median follow-up of 51 months (IQR, 33-81 months). The 3-year overall, disease-specific, recurrence-free and local recurrence-free survival rates were 75%, 82%, 58% and 90%, respectively. The positive vertical margin, submucosal invasion in the endoscopic submucosal dissection specimen and piecemeal resection were significantly associated with disease recurrence after salvage endoscopic submucosal dissection. Salvage endoscopic submucosal dissection is a feasible treatment for local failure after chemoradiotherapy for esophageal squamous cell carcinoma with acceptable long-term outcomes. However, for cases with positive vertical margins and submucosal invasion in the endoscopic submucosal dissection specimen, salvage endoscopic submucosal dissection outcomes were insufficient and additional treatment might be required.

Sections du résumé

BACKGROUND BACKGROUND
Salvage endoscopic submucosal dissection is considered a minimally invasive treatment for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. However, the long-term outcomes have not been fully evaluated. This study investigated the short-term and long-term outcomes of salvage endoscopic submucosal dissection.
METHODS METHODS
Patients who underwent endoscopic submucosal dissection for local recurrence or residual tumor after chemoradiotherapy from January 2006 to December 2017 were retrospectively investigated. Follow-up included endoscopic examination and computed tomography at least once every 6 months after salvage endoscopic submucosal dissection. Risk factors for disease recurrence after salvage endoscopic submucosal dissection were assessed using the Cox hazards model.
RESULTS RESULTS
A total of 30 patients (33 cases of esophageal squamous cell carcinoma: local recurrence, n = 27; residual tumor, n = 6) were included. The median endoscopic submucosal dissection procedure time was 40 min (interquartile range [IQR], 33-58.5 min). En bloc resection was achieved in 31 (94%) of 33 esophageal squamous cell carcinoma cases. One patient with intraoperative perforation did not require surgical intervention and recovered with conservative treatment. A total of 16 patients (53%) had disease recurrence at a median follow-up of 51 months (IQR, 33-81 months). The 3-year overall, disease-specific, recurrence-free and local recurrence-free survival rates were 75%, 82%, 58% and 90%, respectively. The positive vertical margin, submucosal invasion in the endoscopic submucosal dissection specimen and piecemeal resection were significantly associated with disease recurrence after salvage endoscopic submucosal dissection.
CONCLUSIONS CONCLUSIONS
Salvage endoscopic submucosal dissection is a feasible treatment for local failure after chemoradiotherapy for esophageal squamous cell carcinoma with acceptable long-term outcomes. However, for cases with positive vertical margins and submucosal invasion in the endoscopic submucosal dissection specimen, salvage endoscopic submucosal dissection outcomes were insufficient and additional treatment might be required.

Identifiants

pubmed: 33758950
pii: 6183985
doi: 10.1093/jjco/hyab027
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1036-1043

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.

Auteurs

Hidenori Kimura (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Masao Yoshida (M)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yohei Yabuuchi (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Naomi Kakushima (N)

Department of Gastroenterology & Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Yoichi Yamamoto (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Noboru Kawata (N)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kohei Takizawa (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Yoshihiro Kishida (Y)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kenichiro Imai (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Sayo Ito (S)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hirotoshi Ishiwatari (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Matsubayashi (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Hiroyuki Ono (H)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH